The new ‘MN-predict’ platform will allow doctors and scientists to identify those at risk and to design new treatments to prevent them from developing these potentially lethal cancers.
Scientists have made a promising step towards developing a new drug for treating acute myeloid leukaemia, a rare blood disorder. In a study published today in Nature, Cambridge researchers report a new approach to cancer treatment that targets enzymes which play a key role in translating DNA into proteins and which could lead to a new class of cancer drugs.
Scientists at the Cambridge Institute for Medical Research at the University of Cambridge and the Medical Research Council Laboratory of Molecular Biology have taken advantage of revolutionary developments in microscopic imaging to reveal the origins of leukaemia.
The order in which genetic mutations are acquired determines how an individual cancer behaves, according to research from the University of Cambridge, published today in the New England Journal of Medicine.
The first comprehensive computer model to simulate the development of blood cells could help in the development of new treatments for leukaemia and lymphoma, say researchers at the University of Cambridge and Microsoft Research.
A community science initiative – HAEMCODE – has been welcomed for its contribution to our understanding of blood cells and ultimately, to the development of better treatments for leukaemia.
Gavin Garland’s experiences of confronting cancer as a teenager influenced his choice of career as a molecular biologist working on the mechanisms of lymphoma. Now he’s running the Virgin London Marathon 2013 to raise funds for the charity that support the work of his lab.
New drug could treat mixed-lineage leukaemia (MLL).
Cambridge scientists are asking what role stem cells play in how cancer develops, spreads and relapses.
Cancer cells can now be viewed as never before, thanks to cutting-edge imaging tools being developed in Cambridge.
© 2024 University of Cambridge